KR101984192B1 - core-shell capsule including active ingredients and manufacturing method thereof and cosmetic composition including the same - Google Patents

Abstract

According to one embodiment of the present invention, there is provided a pharmaceutical composition comprising a plurality of cores comprising an amphipathic polymer surrounding an active ingredient and a non-ionic surfactant, a shell comprising a phospholipid and surrounding said plurality of cores, Wherein the amphipathic polymer is selected from the group consisting of poloxamer, poly (oxyethylene) -poly (lactic acid), and poly (oxyethylene) -polycaprolactone Wherein the phospholipid comprises a core-shell capsule comprising an active ingredient comprising at least one of hydrogenerated lecithin, hydrogenated phosphatidylcholine, hydrogenated lysophosphatidylcholine and hydrogenated lysoceritin, .

Description

TECHNICAL FIELD The present invention relates to a core-shell capsule containing an active ingredient, a process for preparing the same, and a cosmetic composition containing the core-shell capsule, including active ingredients and manufacturing methods thereof and cosmetic compositions including the same,

The present invention relates to a core-shell capsule comprising an active ingredient, a process for producing the same, and a cosmetic composition comprising the core-shell capsule.

Conventionally, in the field of cosmetics and pharmaceuticals, formulations capable of stably trapping various potentially weak or unstable substances in a product to act on the skin have been developed, but they have not been able to dissolve a sufficient amount to exhibit skin activity It has been difficult to produce such a solution having continuous solubility without change in viscosity due to precipitation and precipitation, thereby making the entire system unstable.

Therefore, in order to increase water solubility of insoluble materials including insoluble substances in various fields, it is necessary to use additives such as liposome using phospholipid, capsule using surfactant, and collector using cyclodextrin, ultra high pressure emulsification device, spray- Development has been made to enhance the bioavailability by facilitating application of water by imparting water solubility through a process such as a public method, an ultrasonic wave, or freeze-drying.

However, the solubilization method in the form of liposome and capsule can increase the reversibility of the active material and the storage stability, but there is a limitation in the content of the poorly soluble substance which can be dissolved, and the method using the cyclodextrin or the excessive polyol There is a problem that the soluble substance can not be collected and the dissolution phenomenon is likely to occur as the content of the internal substance is increased. The higher the content of the additive which is useful for solubilizing, the lower the feeling of use of the product, There is a problem that irritation occurs.

SUMMARY OF THE INVENTION The object of the present invention is to solve the problems of the prior art in that the present invention is intended to solubilize a high content of the active ingredient and lower the melting point of the active ingredient to facilitate solubilization, A core-shell capsule containing an active ingredient that is stable continuously, a method for producing the same, and a cosmetic composition containing the same.

In order to solve this problem, according to one embodiment of the present invention, there is provided a polymer electrolyte membrane comprising a plurality of cores comprising an amphipathic polymer surrounding an active ingredient and a nonionic surfactant, a shell surrounding the plurality of cores, Wherein the active ingredient comprises at least one of ceramide entei, Centella asiatica extract, genistein and daidzein, and the amphipathic polymer is selected from the group consisting of poloxamer, poly (oxyethylene) -poly (lactic acid) Ethylene) -polycaprolactone, wherein the phospholipid comprises an active ingredient comprising at least one of a hydrogenated lecithin, a hydrogenated phosphatidylcholine, a hydrogenated lysophosphatidylcholine and a hydrogenated lysocaturetin Containing core-shell capsules.

The nonionic surfactant may be selected from the group consisting of PEG-40 stearate, PEG-100 stearate, sucrose stearate, sucrose myristate, Sucrose oleate, sucrose palmitate, sucrose laurate, steareth-20, ceteareth-20, polyglyceryl-10 laurate, Polyglyceryl-10 stearate, and polyglycerin-10 pre-stearate.

The active ingredient may comprise an active ingredient comprising 20 to 50% by weight based on the total weight of the core.

The phospholipid may comprise an active ingredient comprising 15 to 50% by weight based on the total weight of the core-shell capsule.

The amphipathic polymer may contain an active ingredient that is equal to or greater than the content of the active ingredient.

The core-shell capsule may contain an active ingredient having an average particle size of 50 to 500 nm when dispersed in water.

According to another embodiment of the present invention, there is provided a method for producing a core aqueous solution, comprising the steps of: preparing a core aqueous solution containing an active ingredient, a nonionic surfactant and an amphipathic polymer; And a third step of spraying and drying the solution of the second step by spraying and drying to form a core-shell capsule, wherein the core-shell capsule comprises an active ingredient and A plurality of cores comprising an amphipathic polymer surrounding a nonionic surfactant and a shell surrounding said plurality of cores comprising said phospholipid, said active ingredients being selected from the group consisting of ceramide endosperm, Centella asiatica extract, Wherein the amphipathic polymer is selected from the group consisting of poloxamer, poly (oxyethylene) -poly (lactic acid), and poly (Oxyethylene) -polycaprolactone, wherein the phospholipid comprises at least one of a hydrogenated lecithin, a hydrogenated phosphatidylcholine, a hydrogenated lysophosphatidylcholine and a hydrogenated lysoceractin The present invention provides a method for producing a core-shell capsule comprising an active ingredient.

The first step comprises a first step of dissolving the active ingredient and the amphipathic polymer in an organic solvent, a step of adding a solution of the first step to water mixed with a nonionic surfactant to prepare a solution constituting a self-assembling capsule And a third step of producing the aqueous solution of the core by evaporating the organic solvent in the solution of the second step.

The weight ratio of the water and the organic solvent on the phospholipid may comprise an active ingredient of 99: 1 to 75:25.

According to still another embodiment of the present invention, there is provided a core-shell capsule comprising the core-shell capsule according to any one of claims 1 to 6, and a cosmetic lotion, a softening lotion, an essence, a cream, a cleansing cream, a cleansing lotion, a cleansing foam, Wherein the core-shell capsule comprises 0.1 to 15% by weight, based on the total weight of the cosmetic composition, of any one of shampoo, gel, vodiesel and body cleanser.

As described above, according to the core-shell capsule containing the active ingredient according to the embodiment of the present invention, the process for producing the same, and the cosmetic composition containing the same, it is possible to make a high content of the active ingredient water- It is easy to be solubilized, and the used additives do not inhibit the feeling of use of the product, and may contain an active ingredient which is continuously stable in the whole system.

1 is a conceptual view of a core-shell capsule according to an embodiment of the present invention.
FIG. 2 is a schematic view showing the manufacturing steps of a core-shell capsule according to an embodiment of the present invention.
3 is a graph showing the DSC analysis results of the Centella asiatica extract (a) and the core-shell capsule (b) according to Example 1. Fig.
4 is a graph showing the DSC analysis results of the ceramide endo (a) and the core-shell capsule (b) according to Example 2. Fig.
5 is a graph showing the results of DSC analysis of the core-shell capsule according to Example 3. Fig.
6 is a graph showing the results of DSC analysis of the core-shell capsule according to Example 4. Fig.
FIG. 7 is a graph showing average particle diameters measured after water-dispersing the core-shell capsules according to Example 2. FIG.
FIG. 8 is a graph showing the results of measuring the quantitative value of the acicoid of the core-shell capsule according to Example 1. FIG.
9 is a graph showing the result of measurement of quantitative values of ceramide entheses of a core-shell capsule according to Example 1. Fig.
10 is a photograph of the core-shell capsules according to Examples 1 to 4 taken before water dispersion.
Fig. 11 is a photograph taken immediately after water-dispersion so that the core-shell capsule according to Examples 1 to 4 was 0.2% by weight.
12 is a photograph of the core-shell capsule according to Examples 1 to 4, which was water-dispersed so as to be 0.2% by weight and was taken at room temperature for 3 minutes.
Fig. 13 is a photograph taken immediately after the core-shell capsule according to Examples 1 to 4 was water-dispersed so as to be 0.2% by weight, heated at room temperature for 3 minutes, and then heated to 40 占 폚 for 3 minutes.
14 is a photograph of a state in which water dispersion is completed after adding the core-shell capsules according to Examples 1 to 4 to 0.2 weight% of water.

BRIEF DESCRIPTION OF THE DRAWINGS The above and other features and advantages of the present invention will become more apparent by describing in detail exemplary embodiments thereof with reference to the attached drawings in which: FIG. The present invention may, however, be embodied in many different forms and should not be construed as limited to the embodiments set forth herein.

Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. In case of conflict, the present specification, including definitions, will control. Also, although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described herein.

Hereinafter, referring to Figs. 1 and 2, a core-shell capsule including an active ingredient according to an embodiment of the present invention will be described in detail.

FIG. 1 is a conceptual view of a core-shell capsule according to an embodiment of the present invention, and FIG. 2 is a schematic view of a core-shell capsule according to an embodiment of the present invention.

1 and 2, a core-shell capsule 20 comprising an active ingredient according to an embodiment of the present invention comprises an active ingredient 2 and an amphipathic polymer 1 And a shell 3 containing a phospholipid surrounding the plurality of cores 10.

That is, a core-shell capsule 20 comprising an active ingredient according to an embodiment of the present invention comprises a plurality of cores 10 comprising an active ingredient 2, an amphipathic polymer 1 and a nonionic surfactant, Is a capsule in which a shell 3 containing a plurality of cores 10 surrounds the core 10 and is coated with a phospholipid in a core-shell form in order to solubilize the active ingredient 2.

When the core-shell capsule 20 containing the active ingredient according to the embodiment of the present invention is added to water, the phospholipid constituting the shell 3 starts to be hydrated, and the core- , The active ingredient in the core-shell capsule 20 may elute and become water-soluble within several minutes to several tens of minutes.

Active ingredient (2) may comprise at least one of ceramide endeon, Centella asiatica extract, genistein and daidzein.

Ceramide has a chemical structure in which sphingoid bases and fatty acids are amide bonded. In the stereostructure, sphingoid bases have at least two asymmetric carbon atoms. Theoretically, there are four kinds of stereoisomers. Four types of sphingoid bases And three kinds of fatty acids are combined into a total of 12 kinds. Of these 12 types, ceramide NP (ceramide NP), which exists in human skin and is easily fermented and synthesized and is most frequently used for cosmetic use, is represented by Formula 1 below. Ceramide Enfine is a combination of fatty acids with sphingoid bases of phytosphingosine. Oleic acid or stearic acid is used as a fatty acid. This is due to the fact that the solubility of a ceramide entyme prepared by synthesizing oleic acid is slightly higher than that of stearic acid synthesized in phytosphingosine It is the most widely used. However, such ceramide entities also have a melting point of about 110 ° C, which is soluble only in oils such as oils. As the content of cosmetic formulations increases, recrystallization and coagulation are limited.

Centella asiatica extract is a trutterpenoid compound that has been extracted for centuries from Gentian kola, which has been used in folk remedies such as wound healing and burn healing, to extract active substances only through extraction, separation and purification. The Centella asiatica extract is composed of an Asian ticoside represented by the following formula 2, an asialic acid represented by the following formula 3, and a Madeca acid represented by the following formula 4, and among these, the Asian ticoside Has a melting point of 235 ~ 238 캜, an acidic acid of 325 ~ 330 캜 and a melting temperature of 255 ~ 270 캜 for Madera acidic acid, which is about 40% by weight of the extract of Centella asiatica . Centella asiatica extract has such a high melting point and unusual structural characteristics that it does not dissolve in oil or water, and it has been found that when producing cosmetic formulations, butyloliglycol, propylene glycol, 1,2-hexanediol, dipropylene It quickly dissolves at a temperature of about 90 ° C in a place such as glycols and is quickly applied to an emulsion preparation step to increase the viscosity and hardness of a cosmetic formulation to manufacture a cosmetic product in a state of preventing the precipitation of Centella asiatica have.

In general, total isoflavones of soybeans are generally composed of 37% by weight of a dideazine represented by the following formula (5), 57% by weight of genistein represented by the following formula (6), and 6% by weight of glycitin. Genistein and daidzein belonging to the isoflavone system have skin activating effects such as active oxygen inhibition, wrinkle improvement and anti-inflammation, but their use for cosmetics has been limited due to their very poor solubility properties. In order to solve the problem of high melting point of 297 ~ 298 ° C for genistein and 315 ~ 323 ° C for daidzein, recently, genistin was liposomized at a very low content, or a material having low concentration at a concentration such as cyclodextrin was circulated and used And it is difficult to manufacture and distribute daidzein, which is one of the more soluble and less -OH groups, than cosmetics in any form.

The active ingredient (2) used in the embodiment of the present invention has a problem that it is difficult to be applied to cosmetic applications because of its high melting point. However, as described below, the core-shell capsule structure The melting point can be drastically lowered, so that it can be easily used for cosmetic applications.

The active ingredient (2) may comprise 20 to 50% by weight based on the total weight of the core (10). If less than 20% by weight is used, the content of the active ingredient contained therein is low, which results in low industrial cost due to low process cost. When the amount exceeds 50% by weight, effective collection of the active ingredient (2) ), Which may adversely affect the formulation.

The amphiphilic polymer (1) is obtained by bonding a hydrophobic polyester polymer (A) and a hydrophilic polymer (B) in the form of a double block (AB), wherein the hydrophobic polyester polymer and the hydrophilic polymer are linked by an ester bond or an amide bond .

Here, the self-assembly of the amphipathic polymer (1) refers to a phenomenon in which a polymer in which a hydrophilic block and a hydrophobic block are bonded to each other spontaneously undergoes fine phase separation in an aqueous solution to have a nano-sized regularity.

The amphiphilic polymer (1) may comprise at least one of poloxamer, poly (oxyethylene) -poly (lactic acid) and poly (oxyethylene) -polycaprolactone bonded in a hydrophilic-hydrophobic form.

However, the present invention is not limited to these, and can be selected and used in accordance with the use and purpose of the amphipathic polymer 1 having self-assembly, or the kind of the active ingredient 2 to be collected using the polymer.

The amphiphilic polymer (1) may contain a content equal to or greater than the content of the active ingredient (2). This is because when the content of the amphipathic polymer 1 is smaller than that of the active ingredient 2 in the step of forming the core 10, the size of the core-shell capsule 20 is relatively large And the core 10 thus formed is manufactured as a non-importer through the secondary and tertiary steps and can be precipitated due to large particle size when dispersed in water.

Nonionic surfactants include PEG-40 stearate, PEG-100 stearate, sucrose stearate, sucrose myristate, sucrose oleate, sucrose oleate, sucrose palmitate, sucrose laurate, steareth-20, ceteareth-20, polyglyceryl-10 laurate, poly Glyceryl-10 stearate, and polyglycerin-10 pre-stearate.

The phospholipid forming the shell 3 of the core-shell capsule 20 may comprise at least one of hydrogenated lecithin, hydrogenated phosphatidylcholine, hydrogenated lysophosphatidylcholine, and hydrogenated lyso lecithin.

Considering the stability and hygroscopicity of the phospholipid, it is most preferable to use hydrogenconed lecithin which is more stable and more commercially available in terms of discoloration, deodorization and moisture absorption during storage and distribution of the product.

The content of the phospholipid may form spherical core-shell capsule 20 particles, preferably 15 to 50% by weight, to be used in an amount of 10% by weight or more based on the total weight of the core-shell capsule 20 . If the amount is less than 15% by weight, the relative content of the active ingredient (2) and the amphipathic polymer (1) is high, which deteriorates the feeling of use and the phospholipid content is low. The core-shell capsule 20 has a good particle formation, but it takes a long time to hydrate due to a high concentration of phospholipid and increases the amount of water and organic solvent used to dissolve the phospholipid, thereby increasing the working time in the spray- Which is undesirable from the viewpoint of process efficiency and has a disadvantage that the content of the active ingredient is relatively low.

The core-shell capsule 20 according to the embodiment of the present invention may have an average particle diameter of 50 to 500 nm when dispersed in water.

Next, a method of manufacturing the core-shell capsule 20 according to the embodiment of the present invention will be described in detail.

The core-shell capsule 20 according to the embodiment of the present invention comprises a first step of preparing a core aqueous solution using the active ingredient (2), the amphiphilic polymer (1) and a nonionic surfactant, (2) a step of adding and mixing the phospholipid dissolved in a solvent to a phospholipid containing phospholipid, and (3) a step of spraying and drying the solution of step 2 by a spray-drying method to form a core-shell capsule 20 containing the active ingredient .

Each step will be described below.

First, the first step is a step of forming a core composed of an amphipathic polymer (1) containing an active ingredient (2) and a nonionic surfactant, wherein the active ingredient (2) and the amphipathic polymer (1) Adding the solution of the first step and the first step to the water mixed with the nonionic surfactant to evaporate the organic solvent in the solution of the second step and the second step of preparing a solution constituting the self- And a third step of producing a dissolved core aqueous solution.

The organic solvent for dissolving the amphiphilic polymer (1) and the active ingredient (2) may be ethanol, acetone, methanol or the like, but not limited thereto, various organic solvents may be used. One or more of these solvents may be selected and used. When two or more of them are used in combination, they may be mixed in the range of 1 to 50 parts by weight.

Next, the second step is a redispersion step of mixing the core aqueous solution with water and a small amount of an organic solvent into a phospholipid dissolved in a phospholipid.

The solvent for dissolving the phospholipids may be a mixture of water and a volatile organic solvent. The weight ratio of water to volatile organic solvent is preferably 99: 1 to 75:25. If the ratio of the organic solvent is more than 25% by weight, the core (10) dissolves in the solvent to elute the active ingredient (2). When the eluted active ingredient (2) is added to the aqueous solution, It is because. The volatile solvents include, but are not limited to, ethanol, methanol, and acetone. One or more solvents may be selected and used. When two or more kinds of the solvents are mixed, they may be mixed in the range of 1 to 50 parts by weight.

Finally, the third step is a step of spraying and drying the solution of the second step by spray-drying to form a core-shell capsule 20 containing the active ingredient (2) And drying the core 10 particles collected by the shell 3 made of a matrix to complete the core-shell capsule 20.

Drying is preferably carried out by a spray-drying method, and the primary dried particles are recovered and further dried for 24 hours by using a vacuum drying system at 40 ° C., and the dried weight loss (2 g / 105 ° C./20 Min., Using an OHAUS MB45 Moisture analyzer) is preferably less than 2% by weight.

As described above, the present invention can be applied to a formulation easily because of its easy-to-handle macro-sized powder, and since it is a water-free solid material having no moisture content, , And after being added to the formulation, it is easily and quickly hydrated by slight heat or weak stirring due to the swelling phenomenon of the phospholipid to elute the internal nanoparticles, so that a high-energy manufacturing process is not necessary.

The cosmetic composition according to another embodiment of the present invention is characterized in that when the core-shell capsule 20 described above is applied to a cosmetic formulation, the moisture is faded and degenerated within several minutes to several tens of minutes by the hydration property of the outermost shell 3 And dissolves in the form of releasing the core 10 inside.

The cosmetic composition is prepared by mixing the core-shell capsule 20 containing the above-described active ingredient (2) with a cosmetic lotion, a softening agent, an essence, a cream, a cleansing cream, a cleansing lotion, a cleansing foam, a pack, a shampoo, a gel, And 0.1 to 15% by weight in any one of the cleaning agents.

Hereinafter, the structure and effect of the present invention will be described in more detail with reference to examples and comparative examples. However, this embodiment is intended to explain the present invention more specifically, and the scope of the present invention is not limited to these embodiments.

Example 1

10 g of poly (oxyethylene) -poly (lactic acid) was dissolved in 400 g of ethanol, and 6 g of Centella asiatica extract was dissolved by heating at 70 캜. 10 g of polyglyceryl-10 stearate was mixed with 4 g of ethanol and heated to 70 DEG C to dissolve, and 400 g of water at 70 DEG C was slowly added thereto. The ethanol phase in which Centella asiatica extract was dissolved was added to the aqueous solution containing polyglyceryl-10 stearate (HY-002 of Hansung EHG Co.). The solution was then transferred to a round bottom flask and connected to a rotary evaporator (Rotavapor R-100, B-100, V-100, BUCHI) maintained at 50 ° C. to evaporate a certain amount of water with ethanol to correct the total volume to 100 ml 100 ml of a core aqueous solution containing Centella asiatica extract was prepared.

Next, 10 g of the hydrogenated lecithin was dissolved in 200 g of water heated to 55 캜 and 15 g of ethanol, 100 ml of the core aqueous solution was added, and the mixture was mixed at 4000 rpm for 5 minutes with a homomixer (Primix TK Mark II Model-2.5) Dried, spray-dried, spray-dried, and spray-dried. The prepared particles were recovered and further dried at 40 ° C. for 24 hours using a vacuum drying oven to completely remove moisture and recovered to prepare a core-shell capsule containing 20 wt% of Centella asiatica extract.

Example 2

10 g of poly (oxyethylene) -poly (lactic acid) was dissolved in 300 g of ethanol, and 10 g of the ceramide enthalpy was dissolved by heating to 70 占 폚. 20 g of Cetearyl-20 was mixed with 5 g of ethanol, and the mixture was heated to 65 DEG C to dissolve, and 300 g of water at 65 DEG C was slowly added thereto. The ethanol phase in which the ceramide enti was dissolved was added to the aqueous phase in which Ceteares-20 was dissolved (HY-002 of Hansung EHG Co.). The solution was then transferred to a round bottom flask and connected to a rotary evaporator (Rotavapor R-100, B-100, V-100, BUCHI) maintained at 50 ° C. to evaporate a certain amount of water with ethanol to correct the total volume to 100 ml Thereby preparing 100 ml of a core aqueous solution containing the ceramide enti.

Next, 10 g of the hydrogenated lecithin was dissolved in 200 g of water heated to 55 캜 and 15 g of ethanol, 100 ml of the aqueous solution of the first nanocapsule was added, and the mixture was stirred at 4000 rpm for 5 minutes with a homomixer (Primix TK Mark II Model- The mixture was mixed to prepare a phospholipid matrix, which was connected to a spray-dry apparatus and dried by spraying. The prepared particles were recovered and further dried at 40 ° C for 24 hours using a vacuum drying oven to completely remove water and recovered to prepare a core-shell capsule containing 30% by weight of ceramide enthalpy.

Example 3

10 g of poly (oxyethylene) -polycaprolactone was dissolved in 500 g of ethanol, and 6.6 g of ceramide globe and 3.4 g of genistein were dissolved by heating at 70 占 폚. 3 g of sucrose stearate was mixed with 6 g of ethanol and heated to 70 DEG C to dissolve. Then, 600 g of water at 70 DEG C was slowly added. The ethanol phase in which ceramide endophil and genistein were dissolved was added to the aqueous sucrose stearate solution (HY-002 manufactured by Hansung EHG Co.). The solution was then transferred to a round bottom flask and connected to a rotary evaporator (Rotavapor R-100, B-100, V-100, BUCHI) maintained at 60 ° C to evaporate ethanol and a certain amount of water, Thereby preparing 100 ml of a core aqueous solution containing both ceramide enti and genistein.

Next, 10 g of the hydrogenated lecithin was dissolved in 250 g of water heated to 60 DEG C and 15 g of ethanol, 100 ml of the core aqueous solution was added, and the mixture was mixed at 4000 rpm for 5 minutes with a homomixer (Primix TK Mark II Model-2.5) Dried, spray-dried, spray-dried, and spray-dried. The prepared particles were recovered and further dried at 40 ° C for 24 hours using a vacuum drying oven to completely remove water and recovered to prepare a core-shell capsule containing 20% by weight of ceramide entities and 10% by weight of genistein.

Example 4

10 g of poloxamer was dissolved in 500 g of ethanol, and 3 g of dide zein was dissolved by heating at 70 캜. Phage-100 Stearate (3 g) and sucrose stearate (2 g) were mixed with 10 g of ethanol, heated to 70 ° C to dissolve, and then 600 g of 70 g of water was slowly added. The ethanol phase in which the daidzein was dissolved was added to the aqueous phase in which phage-100 stearate and sucrose stearate were dissolved (HY-002 of Hansung EHG Co.). The solution was then transferred to a round bottom flask and connected to a rotary evaporator (Rotavapor R-100, B-100, V-100, BUCHI) maintained at 60 ° C to evaporate ethanol and a certain amount of water, To prepare 100 ml of a core aqueous solution containing daidzein.

Next, 12 g of the hydrogenated phosphatidylcholine was dissolved in 300 g of water heated to 60 DEG C and 18 g of ethanol, 100 ml of the core aqueous solution was added, and the mixture was mixed at 4000 rpm for 5 minutes with a homomixer (Primix TK Mark II Model-2.5) Dried, spray-dried, spray-dried, and spray-dried. The prepared particles were recovered and further dried at 40 ° C. for 24 hours using a vacuum drying oven to completely remove water and recovered to prepare a core-shell capsule containing 10% by weight of didezane.

Example 5

4.5 g of hydrogenated phosphatidylcholine was dissolved in 200 g of water heated to 55 캜 and 10 g of ethanol to prepare a phospholipid phase. The remaining steps were performed in the same manner as in Example 1 To prepare a core-shell capsule containing 36% by weight of ceramide endo.

Example 6

The core aqueous solution was prepared in the same manner as in Example 2, 17 g of the hydrogenconed lecithin was dissolved in 200 g of water heated to 55 캜 and 20 g of ethanol to prepare a phospholipid phase. The remaining steps were carried out in the same manner as in Example 1 Core-shell capsules containing 25% by weight of ceramide endophyte were prepared.

Comparative Example 1

The core aqueous solution was prepared in the same manner as in Example 2 and 2 g of the hydrogencontained lecithin was dissolved in 200 g of water heated to 55 캜 and 4 g of ethanol to prepare a phospholipid phase. A core-shell capsule containing 40% by weight of ceramide endo was prepared.

Comparative Example 2

5 g of poly (oxyethylene) -poly (lactic acid) was dissolved in 300 g of ethanol, and 15 g of the ceramide enthalpy was dissolved by heating to 70 캜. 20 g of Cetearyl-20 was mixed with 5 g of ethanol, and the mixture was heated to 65 DEG C to dissolve, and 300 g of water at 65 DEG C was slowly added thereto. The ethanol phase in which the ceramide endo was dissolved was added to the aqueous phase in which Ceteralace-20 was dissolved (HY-002 of Hansung EHG Co.). The solution was then transferred to a round bottom flask and connected to a rotary evaporator (Rotavapor R-100, B-100, V-100, BUCHI) maintained at 50 ° C. to evaporate a certain amount of water with ethanol to correct the total volume to 100 ml Thereby preparing 100 ml of a core aqueous solution containing the ceramide enti.

After preparing the core aqueous solution, 5 g of the hydrogencontained lecithin was dissolved in 200 g of water heated to 55 ° C and 10 g of ethanol to prepare a phospholipid phase. The remaining process was performed in the same manner as in Example 1, Was prepared. ≪ tb > < TABLE >

The composition ratios of Examples 1 to 6 and Comparative Examples 1 to 2 are summarized in Table 1 below.

Room 1 Room 2 Room 3 Room 4 Room 5 Room 6 Rain 1 Rain 2 Poly (oxyethylene) -poly (lactic acid) (g) 10 10 10 10 10 5 The poly (oxyethylene) -polycaprolactone (g) 10 Poloxamer (g) 10 Ceramide Enfee (g) 10 6.6 10 10 10 15 Centella asiatica extract (g) 6 Genistein (g) 3.4 Daid Jane (g) 3 Polyglyceryl-10 stearate (g) 4 Pigment 100 Stearate (g) 3 Cetearyl-20 (g) 3 3 3 3 3 Sucrose stearate (g) 3 2 Phospholipid (g) 10 10 10 12 4.5 17 2 5 Content of active substance (%) 20 30 30 10 36 25 40 53.6

Experimental Example

(1) DSC analysis

DSC analysis was conducted to determine how low the melting points of Examples 1 to 4 were. DSC analysis was submitted to the Korea Polymer Research Institute and the Sungkyunkwan University Joint Instrument for Analysis. The results are shown in FIGS. 3 to 6.

FIG. 3 is a graph showing the results of DSC analysis of the extracts of Centella asiatica (a) and Example 1 (b), FIG. 4 is a graph showing the results of DSC analysis of the ceramide endo (a) 5 is a graph showing the results of DSC analysis of Example 3, and Fig. 6 is a graph showing DSC analysis results of Example 4. Fig.

3, the melting point of the extract of Centella asiatica was 242 캜, but it was confirmed that the melting point of Example 1 was 53 캜 and that the melting point thereof was lowered by 189 캜. Referring to Fig. 4, Deg.] C, the melting point of Example 2 was 47 [deg.] C, and the melting point was 56 [deg.] C lowered.

Referring to FIG. 5, the melting point of Example 3 was 47 ° C., and the melting point of Example 4 was in the range of 42 ° C. to 90 ° C. as shown in FIG. 5, indicating that the melting point was low and the solubilization could be facilitated.

(2) Analysis of average particle size of core-shell capsule

When the core-shell capsule was dispersed in water, the core-shell capsule of Example 2 was added to water so as to analyze the average particle size, and after 3 minutes, the core-shell capsule was dispersed by using a particle size analyzer (MALBERN ZETASIZER Nano-ZS90) The average particle diameter was measured. The results are shown in Fig.

As shown in FIG. 7, it was confirmed that the core-shell capsule according to Example 2 of the present invention had an average particle diameter of about 70 to 177 nm after water dispersion.

(3) Quantitative analysis of Asian Tikoside

In order to analyze the contents of Centella asiatica extract, three components, namely, Asian ticoside, Asian acid and Madeca acid, were present. Respectively.

Measurement of the quantitation value of the Asian ticoside was performed on the core-shell capsule according to Example 1. Measurement of the quantitative value of the asialicoside of the core-shell capsule according to Example 1 was submitted to the Gyeonggi Bio Center for analysis. The results are shown in FIG.

As shown in FIG. 8, it was confirmed that the core-shell capsule according to Example 1 of the present invention contained 8.86% by weight of asiaticoside.

(4) Analysis of quantification of Ceramide Nippi

A measurement of the ceramide endocytosis value of the core-shell capsule according to Example 1 was performed. Measurement of the quantification value of the ceramide entities of the core-shell capsules according to Example 1 was analyzed by Sungkyunkwan University Joint Appliance Research Institute, and the results are shown in FIG.

As shown in FIG. 9, it was confirmed that the core-shell capsule according to Example 1 of the present invention contained 27.55% by weight of ceramide entities.

(5) Analysis of state of water dispersion of core-shell capsule

For the analysis of the condition of the capsules in the water dispersion of the core-shell capsules according to Examples 1 to 4, the water dispersion was added to water so as to be 0.2% by weight, and after 3 minutes at room temperature, The final state of water dispersion of the core-shell capsules was photographed immediately after the temperature was raised to 40 占 폚 for 3 minutes. The results are shown in Figs. 10 to 14. Fig.

As shown in Figs. 10 to 14, it was confirmed that the core-shell capsules according to Examples 1 to 4 were excellent in water-solubility.

Manufacturing example

Next, using the core-shell capsules of Examples 1 to 6 and Comparative Examples 1 and 2, toner formulations of Production Examples 1 to 8 having the compositions shown in the following Table 2 were prepared, respectively.

The toner formulation was prepared by dissolving the water-dispersed core-shell capsules in water at 45 캜 for 10 minutes and thoroughly dispersing them, then adding purified water, glycerin, 1,3-butyleneglycol, betaine, sodium dithiophosphate and sodium hyaluronic acid (1% Dissolved in a stirred solution, and then mixed with alcohol, polysorbate 20, flavor, and phenoxyethanol.

Manufacturing 1
(weight%) Manufacturing 2
(weight%) Manufacturing 3
(weight%) Manufacturing 4
(weight%) Manufacturing 5
(weight%) Manufacturing 6
(weight%) Manufacturing 7
(weight%) Manufacturing 8
(weight%) Purified water to100 to100 to100 to100 to100 to100 to100 to100 glycerin 3 3 3 3 3 3 3 3 1,3-butylene glycol 4 4 4 4 4 4 4 4 Betaine One One One One One One One One Sodium iodide 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 Sodium hyaluronic acid (1%) 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 Purified water 10 10 10 10 10 10 10 10 Example 1 One Example 2 One Example 3 One Example 4 One Example 5 One Example 6 One Comparative Example 1 One Comparative Example 2 One Alcohol 3 3 3 3 3 3 3 3 Polysorbate 20 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 incense 0.08 0.08 0.08 0.08 0.08 0.08 0.08 0.08 Phenoxyethanol 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7

Experimental Example

(1) Hydration and stability analysis

The hydratability and precipitation of the core-shell capsules in the toner formulations according to Preparation Examples 1 to 8 were confirmed. The final prepared toner was measured for the average particle size of core-shell capsules using a particle size analyzer (MALBERN ZETASIZER Nano-ZS90), and the results are shown in Table 3 below.

Manufacturing 1 Manufacturing 2 Manufacturing 3 Manufacturing 4 Manufacturing 5 Manufacturing 6 Manufacturing 7 Manufacturing 8 Particle size
(nm) 118 144 152 388 226 208 Not measurable 1188 Availability O O O O O O X △ Precipitation Mysterious Mysterious Mysterious Mysterious Mysterious Mysterious Sedimentation Sedimentation

As shown in Table 3, in the case of Production Example 7 to which the core-shell capsule of Comparative Example 1 was added in which the total weight of the phospholipids was less than 10% by weight based on the total weight, the core-shell capsule was not hydrated, Exhibited various particle size distributions, and precipitation occurred when added to cosmetic formulations.

In the case of Production Example 8 in which the core-shell capsule of Comparative Example 2 containing less amount of amphipathic polymer than the active ingredient was added, the core-shell capsule did not hydrate well and the core-shell capsule had an excessively large particle size As a result, it was confirmed that the precipitation phenomenon occurred.

On the contrary, in the case of Production Examples 1 to 6 in which the core-shell capsules according to Examples 1 to 6 were added, it was confirmed that the core-shell capsules were hydratable and no precipitation occurred.

(2) Storage stability analysis

The storage stability of the toner formulations according to Production Examples 1 to 4 was confirmed for 4 weeks. The storage stability was measured at 4 ° C, room temperature, 45 ° C and 55 ° C, and the average particle size was measured using a particle size analyzer (MALBERN ZETASIZER Nano-ZS90) for 4 weeks.

The results are shown in Table 4 below. (Unit: nm)

4 ℃ 25 ℃ (room temperature) 45 ° C 55 ° C Production Example 1 Early 118 118 118 118 1 week 118 117 114 114 2 weeks 119 117 115 113 3 weeks 118 117 114 110 4 weeks 118 118 114 108 Production Example 2 Early 144 144 144 144 1 week 142 144 143 140 2 weeks 142 146 142 138 3 weeks 143 143 140 136 4 weeks 145 143 140 135 Production Example 3 Early 152 152 152 152 1 week 150 150 148 150 2 weeks 155 148 145 148 3 weeks 152 153 148 148 4 weeks 153 151 149 145 Production Example 4 Early 388 388 388 388 1 week 385 388 385 360 2 weeks 392 386 387 377 3 weeks 379 390 380 368 4 weeks 383 387 377 363

As shown in Table 4, it was confirmed that the toner formulations to which the core-shell capsules according to Examples 1 to 4 of the present invention were applied had excellent storage stability, and the particle size distributions were not different from those at the initial stage. It was confirmed that there is no possibility of occurrence of problems such as sedimentation and flocculation.

As described above, according to the core-shell capsule containing the active ingredient according to the embodiment of the present invention, the process for producing the same, and the cosmetic composition containing the same, it is possible to make a high content of the active ingredient water- It is easy to be solubilized, and the used additives do not inhibit the feeling of use of the product, and may contain an active ingredient which is continuously stable in the whole system.

While the present invention has been particularly shown and described with reference to exemplary embodiments thereof, it is to be understood that the invention is not limited to the disclosed exemplary embodiments, Of the right.

1: Amphipathic polymer 2: Active ingredient
10: core 3: shell
20: core-shell capsule

Claims (10)

A plurality of cores comprising an amphipathic polymer surrounding the active ingredient and a nonionic surfactant,
And a shell containing a phospholipid surrounding the plurality of cores,
Wherein the active ingredient comprises at least one of ceramide endophyte, Centella asiatica extract, genistein and daidzein,
Wherein the amphipathic polymer comprises at least one of poloxamer, poly (oxyethylene) -poly (lactic acid) and poly (oxyethylene) -polycaprolactone,
Wherein said phospholipid comprises an active ingredient comprising at least one of a hydrogenated lecithin, a hydrogenated phosphatidylcholine, a hydrogenated lysophosphatidylcholine and a hydrogenated lysoceritin. The method of claim 1,
The nonionic surfactant may be selected from the group consisting of PEG-40 stearate, PEG-100 stearate, sucrose stearate, sucrose myristate, Sucrose oleate, sucrose palmitate, sucrose laurate, steareth-20, ceteareth-20, polyglyceryl-10 laurate, Wherein the active ingredient comprises at least one of polyglyceryl-10 stearate and polyglycerin-10 pre-stearate. 3. The method of claim 2,
Wherein the active ingredient comprises an active ingredient comprising from 20 to 50% by weight based on the total weight of the core. 3. The method of claim 2,
Wherein the phospholipid comprises an active ingredient comprising from 15 to 50% by weight based on the total weight of the core-shell capsule. 3. The method of claim 2,
Wherein the amphipathic polymer comprises an active ingredient that is equal to or greater than the content of the active ingredient. 3. The method of claim 2,
Wherein the core-shell capsule comprises an active ingredient having an average particle size of 50 to 500 nm when dispersed in water. A first step of preparing an aqueous core solution comprising an active ingredient, a nonionic surfactant and an amphipathic polymer,
A second step of adding and mixing the aqueous solution of the core to a phospholipid containing phospholipid dissolved in water and an organic solvent, and
And a third step of spraying and drying the solution of the second step by a spray-drying method to form a core-shell capsule,
Wherein the core-shell capsule comprises a plurality of cores comprising an amphipathic polymer surrounding the active ingredient and a non-ionic surfactant and a shell containing the phospholipid surrounding the plurality of cores,
Wherein the active ingredient comprises at least one of ceramide endophyte, Centella asiatica extract, genistein and daidzein,
Wherein the amphipathic polymer comprises at least one of poloxamer, poly (oxyethylene) -poly (lactic acid), and poly (oxyethylene) -polycaprolactone,
Wherein the phospholipid comprises an active ingredient comprising at least one of hydrogenated lecithin, hydrogenated phosphatidylcholine, hydrogenated lysophosphatidylcholine, and hydrogenated lyso lecithin. 8. The method of claim 7,
The first step comprises a first step of dissolving the active ingredient and the amphipathic polymer in an organic solvent,
A second step of adding a solution of the first step to water mixed with a nonionic surfactant to prepare a solution constituting self-assembling capsules, and
And a third step of producing the aqueous core solution by evaporating the organic solvent in the solution of the second step. 9. The method of claim 8,
Wherein the weight ratio of water to the organic solvent on the phospholipid is from 99: 1 to 75:25. A core-shell capsule as claimed in any one of claims 1 to 6, and
Wherein the cosmetic composition comprises any one of cosmetic lotion, astringent lotion, softening lotion, essence, cream, cleansing cream, cleansing lotion, cleansing foam, pack, shampoo, gel,
Wherein the core-shell capsule comprises 0.1 to 15% by weight based on the total weight of the cosmetic composition.

Images